BJR
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
British Journal of Radiology (2008) 81, 490-498
© 2008 British Institute of Radiology
doi: 10.1259/bjr/23571630
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by CHEN, Y-H
Right arrow Articles by CHENG, J C-H
PubMed
Right arrow PubMed Citation
Right arrow Articles by CHEN, Y-H
Right arrow Articles by CHENG, J C-H

Full paper

Definitive chemoirradiation for resectable head and neck cancer: treatment outcome and prognostic significance of MRI findings

Y-H CHEN, MD1,2, J J-M JIAN, MD, K-Y CHAN, MD, S Y TSAI, MD, S H CHENG, MD, K-C L YEN, MD and J C-H CHENG, MD, PhD1,2,6

1 Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, 2 Cancer Research Center, National Taiwan University College of Medicine, Taipei, Departments of 3 Radiation Oncology, 4 Diagnostic Radiologyand Otolaryngology — Head and 5 Neck Surgery, Koo Foundation Sun Yat-Sen Cancer Center, Taipei and 6 Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan

Correspondence: Jason Chia-Hsien Cheng, Division of Radiation Oncology, Department of Oncology, National Taiwan University Hospital, No 7 Chung-Shan South Road, Taipei 100, Taiwan. E-mail: jasoncheng{at}ha.mc.ntu.edu.tw

The aim of this study was to evaluate the outcome and prognosticators for patients with resectable head and neck cancer (RHNC) undergoing definitive concurrent chemotherapy and radiotherapy (CCRT). In total, 110 RHNC patients receiving definitive CCRT to defer radical surgery were enrolled. Radiotherapy was given as either 2 Gy once daily with 70 Gy, or 1.2 Gy twice daily with 74.4 Gy. Chemotherapy involved the administration of 5-fluorouracil and cisplatin in two concomitant and two post-radiotherapy adjuvant cycles. 3 months after CCRT, MRI was performed to evaluate the response and determine further treatment plans. Survival outcome was calculated by the Kaplan–Meier method. Log-rank test and Cox regression analyses were used to estimate the significance of prognosticators. 4-year local-regional control, distant metastasis-free survival, disease-free survival and overall survival rates were 76.1%, 85.6%, 67.5% and 53.2%, respectively. Local recurrence (odds ratio = 4.09; p<0.0001) and T3/T4 stage (odds ratio = 2.34; p = 0.01) were the independent factors associated with poor survival. T stage (odds ratio = 3.29; p = 0.03) and/or remission status on post-CCRT MRI (odds ratio = 7.22; p<0.0001) were significantly associated with local control, distant metastasis-free survival and disease-free survival. 13 of 20 patients with imaging residuum had local recurrence, compared with 12 of 89 with complete remission (4-year local control rate of 27% vs 86%; p<0.0001). Post-CCRT MRI may thus be used to predict the chance of a successful non-surgical approach.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
BJR DMFR IMAGING  ALL BIR JOURNALS 
Copyright © 2008 by the British Institute of Radiology.